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Abstract
Background: The Intensified Case Finding (ICF) tool was approved for TB screening in 2011; however there is still
paucity of robust data comparing yields of the different ICF screening modalities. We compared yields of three
different screening modalities for TB among Patients Living with HIV (PLHIV) in Uganda in order to inform National
TB Programs on the most effective TB screening method.
Methods: This was a retrospective quasi-experimental study conducted at an Out-Patient HIV/AIDS clinic in
Uganda. We set out to determine yields of three different TB screening modalities at three time periods: 2006/07
where Passive Case Finding (PCF) was used. Here, no screening questions were administered; the clinician
depended on the patient’s self report. In 2008/09 embedded Intensified Case Finding Tool (e-ICF) was used; here a
data capture field was added to the patient clinical encounter forms to compel clinicians to screen for TB
symptoms. In 2010/11 Independent Intensified Case Finding Tool (i-ICF) was used; here a screening data collection
form, was used, it had the same screening questions as e-ICF. Routine clinical data, including TB status, were
collected and entered into an electronic clinical care database. Analysis was done in STATA and the main outcome
estimated was the proportional yield of TB cases for each screening modality.
Results: The overall yield of TB cases was 11.18 % over the entire period of the study (2006 – 2011). The
intervention–specific yields were 1.86 % for PCF, 14.95 % for e-ICF and 12.47 % for i-ICF. Use of either e–ICF (OR:
9.2, 95 % CI: 4.81-17.73) or i– ICF (OR: 7.7, 95 % CI: 4.02-14.78) significantly detected more TB cases compared to
PCF (P <0.001). While the yields of the Active Case Finding modalities (e-ICF & i-ICF) were not significantly
different (OR: 0.98, 95 % CI 0.76-1.27, P = 0.89).
Conclusion: The active screening modalities (e-ICF & i-ICF) had a comparable TB yield and were eight to nine
times more efficient in identifying TB cases when compared to the PCF. Cost effectiveness studies would be
informative.
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Background
The World Health Organization’s (WHO) directly ob-
served short course strategy (DOTs) was intended to
achieve a treatment success rate (TSR) of >85 % and a
case detection rate (CDR) of >70 % with a view to de-
creasing Tuberculosis (TB) incidence by 11 % annually
[1]. However, despite the improvement in TSR from
43 % in 1994 [2] to 86 % in 2013 [3], CDR has stabilized
at around 60 % since 2005 [4] and TB incidence remains
generally higher in most low and middle-income coun-
tries [5]. Several reasons have been advanced to explain
this phenomenon including the HIV pandemic and use
of passive case finding approach which rely on waiting
for patients to self report the signs and symptoms of TB.
Recent TB prevalence surveys have suggested that there
is a high burden of undiagnosed TB [6–9]. This is cor-
roborated by the fact that only 6 million new TB cases
were reported to WHO in 2014, out of an estimated 9.6
million TB patients globally [3]. Subsequently TB inci-
dence has only decreased by only 1 % annually and not
the anticipated 11 % [4]. Thus, the DOTs strategy which
mainly uses passive case finding approaches has failed
TB control efforts especially in countries which have a
generalized TB epidemic (prevalence greater than 1 % of
the general population) [10, 11].
In recognition of this failure, WHO recommended use
of the intensified case finding tool for TB screening in
2004 in order to improve TB case detection or TB yield
especially among high-risk persons such as persons liv-
ing with HIV [12]. The different ICF modalities have
been used in isolation, and they have been associated
with an increased yield of TB patients [13–17]. However
there is paucity of robust data trying to compare differ-
ent ICF modalities in the same setting.
We set out to compare the yield of three screening
modalities among people living with HIV (PLHIV) in a
peripheral health facility in Uganda. These screening
modalities were: (i) Passive case finding (PCF), where no
screening questions were administered and the clinicians
depended on the patients’ signs and symptoms, (ii) em-
bedded intensified case finding (e-ICF), where a data
capture field was added to the patient encounter forms
to compel clinicians to screen for TB, and (iii) independ-
ent intensified case finding (i-ICF) a data collection form
was utilized. The form had the same screening questions
as e-ICF except that it was a standalone A4 form. The
primary aim of the study was to identify which screening
modality had the best yield.
Methods
Study design and setting
We conducted a retrospective quasi-experimental study of
People Living with HIV (PLHIV) attending a Private Not
for Profit (PNFP) HIV/AIDS clinic offering comprehensive
services in Jinja district, Eastern Uganda. The HIV clinic
was started in September 2004 following with the PEPFAR
initiative.
Study population
The study population was HIV-positive patients enrolled
in HIV care between 2006 and 2011. Patients that were
found to be HIV positive were enrolled into the clinic
and then they were treatment according to the Ugandan
HIV/AIDS treatment guidelines [18]. By 31st December
2011, the clinic had 2800 PLHIV clients registered in
care and alive; 1,040 of these (37.14 %) were males, 313
(11.17 %) were children under the age of 14 years and
1,934 (69.07 %) were on Antiretroviral therapy (ART).
Over the study period the clinic had two doctors, four
Nurses, two Laboratory, two Counselors, two data
clerks, two pharmacy technicians and a receptionist, the
same staff was kept over the whole study period. All the
patients who came to the clinic got their files from the
reception and were directed to the Nurse in-charge for
the assessment of vital signs. If the patient had no com-
plaints, they were sent to another nurse who gave them
a drug refill. The patients were allowed to get a drug re-
fill without seeing the doctor twice but it was a must
every 6 months. Here the patients had their vitals taken
by the nurse, who sent them to the doctor. The doctor
assessed the patient and also requested for laboratory
tests mainly a Cluster for Differentiation 4 (CD4), Liver
Function Tests (LFT’s) and Renal Function Tests
(RFT’s). Then after passing by the laboratory, the patient
would get the medicine from the pharmacy. However, if
the patient was very ill, the patient was sent to the doc-
tor immediately. The doctor then did the vitals as well
as assessing the patient and offered the necessary care
and treatment. Patients were often given bi-monthly ap-
pointments. Any patient who missed their appointment
was given a call the following day. A home visit was
done if the patient did not return to the clinic two weeks
after the appointment. This was done to ascertain why
the patient missed their appointment. But otherwise pa-
tients were allowed to visit the clinic any day in case of
emergencies. Sometimes the patient was sent to the
counselor but was mainly for either patients who are
starting Anti-retroviral Treatment (ART) or those who
were thought to be non-adherent. TB screening could be
done by any staff along the process.
Intervention description
Three different strategies were used to identify potential
TB patients: passive case finding, embedded intensified
case finding, and an independent paper-based intensified
case-finding tool, the different modalities were used ex-
clusively. Whenever there was a change in intervention,
the clinic staffs were taught about the new intervention
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at the same time, and they were oriented on the new
tools to use.
With Passive Case Finding (PCF), no screening ques-
tions were administered since the identification of sus-
pected TB cases was based on patients’ self-reports of
any of the TB-related symptoms (i.e., current cough,
fever, weight loss or night sweats) without prompting by
a clinician. This was the standard of care between 2006
and 2007.
Between 2008 and 2009, a data capture field was added
to the patient clinical encounter forms to compel clini-
cians to screen for TB symptoms for each patient. The
data capture field necessitated the clinician to ask if the
patients had any of the following symptoms and signs,
current cough, drenching night sweats, night fevers, un-
explained weight loss > 10 % of the body weight, and all
respondents reporting any of the above-mentioned TB-
related symptoms were considered for full TB evalu-
ation. This underlies what we referred to as the embed-
ded Intensified Case Finding (e- ICF) strategy.
Finally, the National TB and Leprosy Program of
Uganda (NTLP) in collaboration with the AIDS Control
Program (ACP) introduced a screening data collection
form on which details and symptom questionnaire re-
sults are recorded each time a PLHIV attends the clinic
(independent paper based Intensified Case Finding tool
(i-ICF)). This i-ICF approach used the same screening
questions as the e-ICF.
Inclusion and exclusion criteria
We included all patients who had at least one clinic visit
between 1st January 2006 and 31st December 2011
(6 years).
The following patients were excluded, patients known
to have TB or on TB treatment and cases missing signifi-
cant variables. These were Basal Mass Index (BMI) ≤ 15
or ≥ 40, Cluster for differentiation 4 (CD4+) > 1500 cells/
mm3 and were the age variable could not be determined.
Data collection methods and procedures
During patient visits clinic staff prospectively entered
into an electronic database the clinical parameters, ART
initiation and adherence, WHO stage, toxicities, and op-
portunistic infections.
We extracted data of all the patients who had a cough
for two weeks or more, fevers, weight loss or night sweats.
We then corroborated this data with the health facility
paper–based TB recording and reporting tools of the
Uganda NTLP. These were: the TB laboratory registers for
persons undergoing sputum examination for suspected
TB; the unit TB treatment register and TB pharmacy dis-
pensing logs for those who received treatment for TB.
Where data was unclear or inconsistent, we validated
these by reviewing clinical notes from the patient charts.
Outcome measures
The study main outcome of interest was yield of tubercu-
losis on using different screening modalities. The TB yield
was defined as a percentage of the patients that were
found with TB when a particular screening modality was
used. The screening modality used was dependant on the
time period. The different yields were determined by get-
ting a proportion of patients with TB indentified by a par-
ticular TB screening modality over the number of active
patients when the modality was used.
We defined a patient with Tuberculosis according to
the guidelines of the Uganda NTLP as follows: a person
with a sputum smear microscopy result positive for TB
or a patient with signs and symptoms of Tuberculosis
with a chest–radiograph suggestive of TB or a patient
with signs and symptoms of Tuberculosis who is
diagnosed to have Tuberculosis by a competent Medical
Officer [19].
Patients that were identified as TB suspects by the
various screening modalities were sent for further inves-
tigations. The investigations often used were sputum mi-
croscopy, chest radiography, abdominal ultrasonography,
lymph node biopsy and Fine needle aspirate for micros-
copy. Mycobaterial culture and Xpert MTB/RIF tests
were either not used because of the high costs or not be-
ing readily available at the time. The diagnosis was done
based on the investigation and occasionally on clinical
presentation alone.
Data analysis
We exported the data from spreadsheet (Microsoft Excel
version 2010) into Intercooled Stata version 11.2 (Stata-
Corp, College Station, Texas, USA) for a complete cases
analysis cases missing significant variables were excluded).
We summarized demographic and outcome data into fre-
quencies, percentages and measures of central tendency
the median and mean. We explored the association be-
tween baseline characteristics and TB by univariate ana-
lysis (logistic regression) with crude odds ratios (OR) and
95 % confidence intervals. Statistical tests for association
were two–sided and considered significant if P < 0.05. We
included potential determinants of TB with P < 0.25 at
univariate level, in a multivariable logistic regression
model to estimate their adjusted odds ratios (aOR). In the
time–to–event analysis were the start and end point was
the beginning of a two year period when a screening mo-
dality was used, the censorships were death, lost to follow
up, having TB or being on TB treatment. We compared
the TB Case Detection Rate (CDR) of the screening inter-
ventions across the distinct cohorts enrolled during the
three study periods: between 1st January and 31st Decem-
ber of 2006 to 2007, 2008 to 2009 and from 2010 to 2011.
The yield per screening modality was calculated using
the number of TB cases detected over the number of
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active patients at the time. We then compared the yield
of PCF to both e-ICF and i-ICF and that of e-ICF to i-
ICF. The Case Detection Rate per 1,000 person years of
observation (PYO) was also computed, and its corre-
sponding 95 % confidence interval using the Wald statis-
tic. We plotted survival curves using the Kaplan–Meier
technique to depict this difference in yield of TB using
the three different screening strategies. We report our
findings in accordance with ‘The Reporting Quality of
Non Randomized Evaluations of Behavioral and Public
Health Interventions’ (TREND) statement [20].
Results
Socio-demographic and clinical characteristics of the
patients
Between 2006 and 2011, a total of 2800 patients were
enrolled in HIV care at the HIV care clinic in Jinja
district, Eastern Uganda. Of the 2800, 342 patients
(63 patients had prevalent TB, while 279 had extreme
variables, 246 had a BMI ≤ 15 or ≥ 40, while 21 had a
CD4+ > 1500 cells/mm3 and 12 had an age <0 years
of age) were excluded, leaving 2458 patients who were
considered for the final analysis (Fig. 1). The cohort
had 535 patients between 2006/07, 876 patients between
2008/09 and 1047 between 2010/11. The mean age was
34.8 years (SD: 11.5). Majority of the patients (61.2 %) were
females and 149 (6.06 %) had a formal education (Table 1).
The baseline median CD4+ cell count was 505 cells/mm3
(IQR 200 – 720 cells/mm3), while the mean BMI was 24.9
(SD: 5), and 1,912 (78 %) PLHIV were on ART. Participants
diagnosed with Tuberculosis were more likely to be older
(aOR: 1.02, 95 % CI: 1.01 – 1.04, p < 0.001), have a tertiary
education (aOR: 2.38, 95 % CI: 1.41 – 4.04, p = 0.001), to be
Patients in care at HIV clinic









Number included in the analysis
n=2,458
Fig. 1 Flow diagram of study participants
Table 1 Factors associated with tuberculosis among PLHIV between 2006 and 2011
Variable All cohort TB No TB Univariate Multivariate
N = 2,458 (100) n = 275 (11.18) n = 2,183 (88.81) OR 95 % CI P–value aOR 95 % CI P–value
Age (years)
Mean (sd) 34.8 (11.5) 38.0 (11.7) 34.4 (11.5) 1.02 1.01 – 1.04 <0.001 1.03 1.01 – 1.03 <0.001
Gender
Female 1,505 (61.2) 175 (63.6) 1,329 (60.9) 1 0.38
Male 953 (38.7) 100 (36.4) 854 (39.1) 1.13 0.87 – 1.46 - - -
Education#
None 501 (21.8) 40 (15) 461 (22.7) 1 <0.001 1
Primary 993 (43.2) 134 (50.4) 859 (42.3) 1.80 124 – 2.61 1.72 1.18 – 2.51 0.005
Secondary 654 (28.5) 62 (23.3) 592 (29.1) 1.20 0.79 – 1.83 1.22 0.80 – 1.86 0.350
Tertiary 149 (6.5) 30 (11.3) 119 (5.9) 2.90 1.73 – 4.86 2.38 1.41 – 4.04 0.001
Missing 161 (6.5) 9 (3.27 %) 152 (6.96 %)
ART Status
No 546 (22) 22 (8) 524 (24) 1 <0.001 1
Yes 1912 (78) 253 (92) 1659 (76) 3.64 2.32–5.71 3.38 2.16 – 5.32 <0.001
Baseline CD4+
Median (IQR) 505 (200–720) 552 (286–782) 496 (192–712) 1.00 1.00.–1.00 <0.01 1.00 1.00 – 1.00 0.034
BMI
Mean (sd) 24.9 (5) 26.1 (5.3) 24.2 (4.9) 1.05 1.03–1.08 <0.001 1.05 1.02 – 1.07 0.001
Abbreviations: ART antiretroviral therapy, aOR odds ratio adjusted for all variables with p < 0.25, BMI basal mass index, CD4+ cluster of differentiation, CI confidence
interval, OR crude odds ratio, IQR inter quartile range, sd standard deviation, TB Tuberculosis, *Significance level of p < 0.05, () refers to percentage unless stated
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on ART (aOR: 3.38, 95 % CI: 2.16 – 5.32, p < 0.001) and
have a higher BMI (aOR: 1.05, 95 % CI: 1.02 – 1.07, p <
0.001), (Table 1). Differences in the CD4+ cell counts were
not statistically significant (p = 0.034).
Yield of Tuberculosis cases by screening modality
When PCF was introduced in 2006, the yield of TB was
1.87 % (10/535) increasing to 14.95 % (131/876) when e–
ICF was introduced in 2008. The yield then decreased to
12.79 % (134/1,047) when i–ICF was introduced in 2011.
Each of the modalities was used for a period of two years.
This translated into a TB Case Detection Rate (CDR) of
15.4/1,000 PYO (95 % CI 5.9 – 24.9) for PCF, 137.8/1,000
PYO (95 % CI 115.8 – 159.7) for e-ICF and 123.9/1,000
(95 % CI 104.3 – 143.6) for i–ICF, respectively (Table 2).
This increment in the yield of TB was statistically signifi-
cant when either e–ICF (OR: 9.2, 95 % CI: 4.81-17.73, P =
0.0001) or i–ICF (OR: 7.7, 95 % CI: 4.0-14.78, P = 0.0001)
were introduced. However, there was no statistically signifi-
cant difference in the yield of TB when i-ICF was compared
to e-ICF (OR: 0.98, 95 % CI: 0.76-1.3, P = 0.89). These
findings are further illustrated in Fig. 2.
Discussion
The purpose of this study was to compare the yield of
three different screening modalities among People Living
with HIV (PLHIV). We found that either Active Case
Finding modality (e-ICF or i-ICF) had a similar yield but it
was 8-9 fold higher to the TB yield when PCF was used.
Use of any Active Case Finding (ACF) method for
screening for TB, had a higher yield compared to the
passive method (PCF). The better performance of active
case finding strategies in our study in comparison to the
Passive Case Finding corroborates results of other stud-
ies done in Uganda [14, 16, 17, 21, 22] which showed a
higher yield of Tuberculosis with active screening. Our
study is also consistent with a systematic review by
Kranzer and colleagues [13] that found a median preva-
lence of 8.6 % (3.6 % - 24.7 %) in antiretroviral clinics in
sub-Saharan Africa. We therefore call for the extensive
implementation of the ICF tool for screening for TB, this
will not only increase the Case Detection Rate but
patients will be indentified early before infecting a lot
more people.
Using of e-ICF for TB case finding was found with a
comparable yield to using a standalone ICF form for
Table 2 TB yield per screening modality
TB screening modality N (%) TB cases (%) TB Yield Time at riska CDRb 95 % CI
Passive Case Finding 535 (21.8) 10 (3.7) 1.86 % 647 15.4 5.9 – 24.9
Embedded – ICF 876 (35.6) 131 (47.6) 14.95 % 951 137.8 115.8 – 159.7
Independent – ICF 1047 (42.6) 134 (48.7) 12.47 % 1081 123.9 104.3 – 143.6
Any screening modality 2458 (100) 275 (100) 11.18 % 2679 102.7 91.2 – 114.1
Abbreviations: ICF intensified case finding, CI confidence interval, TB tuberculosis, N number of patients screened, PYO person years of observation
aTime at risk is in person years of observation
bCase detection Rate per 1000 person years of observation
Fig. 2 Graph showing the Cumulative Hazard curves of the three TB Screening modalities
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screening. This is one of the few studies to compare 2
active screening modalities. The use of independent ICF
form raises concerns of operational feasibility such as
stock outs and patients being screened but records lost.
We recommend the embedding of screening tools into
the patient clinical encounter forms not only for TB but
also other diseases, such as diabetes, were joint screen-
ing initiatives have proven effective [23–28].
Despite the TB yields of the two Active Case Finding mo-
dalities being comparable. That of e-ICF was 2.48 percent-
age points higher than i-ICF. We theorize that since in e-
ICF the Intensified Case Finding Tool is embedded into the
patient encounter forms. It was easier for the health workers
to screen almost all patients they had an encounter with.
Limitations
Our retrospective quasi-experimental study was not
without limitations particularly the completeness and in-
tegrity of the data set which we circumvented by corrob-
orating information from patient clinical notes and
excluding missing data. We did not adjust for differences
in time on HIV care, since longer duration on ART has
been found to be protective. However, we adjusted for
age, sex, CD4+ cell counts, body mass index and educa-
tion status. Additionally, there could have been a detec-
tion bias due to the use of sputum smear microscopy,
which has even lower sensitivity in patients with HIV,
could have led to the underestimation of the burden of
TB in this cohort particularly between 2006 and 2007
with very few events. Nonetheless, sputum smear mi-
croscopy remains the mainstay of TB diagnosis in per-
ipheral HIV clinics due to implementation difficulties of
scaling up the more robust Xpert MTB/RIF as per
WHO recommendations [29].
Conclusion
The active screening modalities (e-ICF & i-ICF) had a
comparable TB yield but were eight to nine times more
efficient in identifying TB cases when compared to the
PCF. Therefore either case finding modality can be used
for screening for TB. Embedding the ICF form into the
patient’s clinical encounter form is more feasible. Future
research could examine operational issues such as ac-
ceptability by health providers particularly in the private
sector and logistical considerations of the ICF strategy.
We also recommend same assessment but using diag-
nostic modalities with a better sensitivity and specificity
like Xpert MTB/RIF.
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